R

Rachel O. Abelman

Massachusetts General Hospital

ORCID: 0000-0002-3946-7420

Publishes on HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology. 67 papers and 494 citations.

PubIndex Score85Top 15% · mid-careerHow it's scored

67Publications

494Total Citations

First publication: 2014First senior author: 2021

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research

Top publicationsby citations

Mechanisms of Resistance to Antibody–Drug Conjugates

Rachel O. Abelman, Aditya Bardia, Bogang Wu et al.|Cancers|2023

Cited by 135

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

Laura M. Spring, Aditya Bardia, Sara M. Tolaney et al.|Annals of Oncology|2023

Cited by 77

Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.

Rachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Journal of Clinical Oncology|2023

Cited by 53

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Aditya Bardia, Leif W. Ellisen, Seth A. Wander et al.|Clinical Cancer Research|2024

Cited by 43

Bioinformatic Approach to the Genetics of Preeclampsia

Elizabeth W. Triche, James F. Padbury, Alper Uzun et al.|Obstetrics and Gynecology|2014

Cited by 42